Trevena, Inc. (NASDAQ:TRVN – Free Report) – Research analysts at HC Wainwright issued their Q1 2025 EPS estimates for Trevena in a research note issued on Thursday, November 14th. HC Wainwright analyst D. Tsao anticipates that the biopharmaceutical company will post earnings per share of ($0.37) for the quarter. HC Wainwright currently has a “Neutral” rating and a $5.00 price objective on the stock. The consensus estimate for Trevena’s current full-year earnings is ($32.25) per share. HC Wainwright also issued estimates for Trevena’s Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.37) EPS and Q4 2025 earnings at $0.18 EPS.
Trevena (NASDAQ:TRVN – Get Free Report) last announced its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($5.79) earnings per share for the quarter. The business had revenue of $0.28 million during the quarter.
Check Out Our Latest Report on Trevena
Trevena Stock Down 0.6 %
Shares of NASDAQ TRVN opened at $1.68 on Friday. The firm’s 50-day simple moving average is $3.05 and its 200 day simple moving average is $5.64. The stock has a market cap of $1.44 million, a P/E ratio of -0.04 and a beta of 1.08. Trevena has a fifty-two week low of $1.13 and a fifty-two week high of $19.23.
Trevena Company Profile
Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.
Read More
- Five stocks we like better than Trevena
- Buy P&G Now, Before It Sets A New All-Time High
- How Whitestone REIT Is Transforming Sun Belt Retail Growth
- How to Use the MarketBeat Stock Screener
- Top-Performing Non-Leveraged ETFs This Year
- Stock Sentiment Analysis: How it Works
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.
